Magnetic resonance imaging pattern of bone marrow involvement as a new predictive parameter of disease progression in newly diagnosed patients with multiple myeloma eligible for autologous stem cell transplantation

British Journal of Haematology

Volumn 165, Issue 6, 2014, Pages 777-785

  Song, Moo Kon ^a   Chung, Joo Seop ^a   Lee, Je Jung ^b   Min, Chang Ki ^c   Ahn, Jae Sook ^b   Lee, Sang Min ^d   Shin, Dong Yeop ^e   Bae, Sung Hwa ^f   Hong, Junshik ^g   Lee, Gyeong Won ^h   Lee, In Sook ^a   Shin, Ho Jin ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Chonnam National University Research Institute of Medical Sciences   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Korea Cancer Center Hospital   (South Korea)

^f Medical Center 3056 6   (South Korea)

^g Gachon University   (South Korea)

^h Gyeongsang National University   (South Korea)

Author keywords

Cytogenetics; Magnetic resonance imaging; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; DEXAMETHASONE; DOXORUBICIN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD LEVEL; BONE MARROW; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CHROMOSOME ANALYSIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; SURVIVAL RATE;

CYTOGENETICS; MAGNETIC RESONANCE IMAGING; MULTIPLE MYELOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84901692994     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12820     Document Type: Article

References (18)

1. Ailawadhi, S., Abdelhalim, A.N., Derby, L., Mashtare, T.L., Miller, K.C., Wilding, G.E., Alberico, R.A., Gottlieb, R., Klippenstein, D.L., Lee, K. & Chanan-Khan, A.A. (2010) Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer, 116, 84-92.
2. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. & Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. New England Journal of Medicine, 335, 91-97.
3. Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. & Crowley, J. (1999) Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 93, 55-65.
4. Baur, A., Bartl, R., Pellengahr, C., Baltin, V. & Reiser, M. (2004) Neovascularization of bone marrow in patients with diffuse multiple myeloma: a correlative study of magnetic resonance imaging and histopathologic findings. Cancer, 101, 2599-2604.
5. Bladé, J., Rosiñol, L., Sureda, A., Ribera, J.M., Díaz-Mediavilla, J., García-Laraña, J., Mateos, M.V., Palomera, L., Fernández-Calvo, J., Martí, J.M., Giraldo, P., Carbonell, F., Callís, M., Trujillo, J., Gardella, S., Moro, M.J., Barez, A., Soler, A., Font, L., Fontanillas, M. & San Miguel, J. (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood, 106, 3755-3759.
6. Child, J.A., Morgan, G.J., Davies, F.E., Owen, R.G., Bell, S.E., Hawkins, K., Brown, J., Drayson, M.T. & Selby, P.J. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New England Journal of Medicine, 348, 1875-1883.
7. Dimopoulos, M.A., Moulopoulos, L.A., Datseris, I., Weber, D., Delasalle, K., Gika, D. & Alexanian, R. (2000) Imaging of myeloma bone disease-implications for staging, prognosis and follow-up. Acta Oncologica, 39, 823-827.
8. Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854.
9. Fermand, J.P., Katsahian, S., Divine, M., Leblond, V., Dreyfus, F., Macro, M., Arnulf, B., Royer, B., Mariette, X., Pertuiset, E., Belanger, C., Janvier, M., Chevret, S., Brouet, J.C. & Ravaud, P. (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. Journal of Clinical Oncology, 23, 9227-9233.
10. Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412-3420.
11. Hastings, R.J., Cavani, S., Bricarelli, F.D., Patsalis, P.C. & Kristoffersson, U. (2007) Cytogenetic Guidelines and Quality Assurance: a common European framework for quality assessment for constitutional and acquired cytogenetic investigations. European Journal of Human Genetics, 15, 525-527.
12. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757.
13. Moulopoulos, L.A. & Dimopoulos, M.A. (1997) Magnetic resonance imaging of the bone marrow in hematologic malignancies. Blood, 90, 2127-2147.
14. Moulopoulos, L.A., Varma, D.G., Dimopoulos, M.A., Leeds, N.E., Kim, E.E., Johnston, D.A., Alexanian, R. & Libshitz, H.I. (1992) Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology, 185, 833-840.
15. Moulopoulos, L.A., Gika, D., Anagnostopoulos, A., Delasalle, K., Weber, D., Alexanian, R. & Dimopoulos, M.A. (2005) Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Annals of Oncology, 16, 1824-1828.
16. Moulopoulos, L.A., Dimopoulos, M.A., Christoulas, D., Kastritis, E., Anagnostou, D., Koureas, A., Roussou, M., Gavriatopoulou, M., Migkou, M., Iakovaki, M., Gkotzamanidou, M., Tasidou, A. & Terpos, E. (2010) Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia, 24, 1206-1212.
17. Moulopoulos, L.A., Dimopoulos, M.A., Kastritis, E. & Christoulas, D., Gkotzamanidou, M., Roussou, M., Koureas, A., Migkou, M., Gavriatopoulou, M., Eleutherakis-Papaiakovou, E., Gika, D., Koutoulidis, V. & Terpos, E. (2012) Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. American Journal of Hematology, 87, 861-864.
18. Smith, D.B., Scarffe, J.H. & Eddleston, B. (1988) The prognostic significance of X-ray changes at presentation and reassessment in patients with multiple myeloma. Hematological Oncology, 6, 1-6.